William M Pardridge
#54,584
Most Influential Person Now
Physician, scientist and businessman; Distinguished Professor Emeritus at UCLA
William M Pardridge's AcademicInfluence.com Rankings
William M Pardridgebusiness Degrees
Business
#210
World Rank
#231
Historical Rank
Accounting
#13
World Rank
#15
Historical Rank
William M Pardridgephilosophy Degrees
Philosophy
#1741
World Rank
#3104
Historical Rank
Logic
#299
World Rank
#606
Historical Rank
Download Badge
Business Philosophy
Why Is William M Pardridge Influential?
(Suggest an Edit or Addition)William M Pardridge's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The blood-brain barrier: Bottleneck in brain drug development (2011) (1972)
- Blood-brain barrier delivery. (2007) (1003)
- Drug Transport across the Blood–Brain Barrier (2012) (758)
- Brain metabolism: a perspective from the blood-brain barrier. (1983) (724)
- Blood-brain barrier drug targeting: the future of brain drug development. (2003) (647)
- Brain drug delivery of small molecules using immunoliposomes. (1996) (632)
- Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative western blotting and in situ hybridization. (1990) (553)
- Drug Targeting to the Brain (2007) (544)
- TRANSPORT OF METABOLIC SUBSTRATES THROUGH THE BLOOD‐BRAIN BARRIER 1 (1977) (523)
- Transport of protein-bound hormones into tissues in vivo. (1981) (452)
- Drug and gene targeting to the brain with molecular trojan horses (2002) (446)
- Blood-brain barrier biology and methodology. (1999) (437)
- Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins (1990) (433)
- CNS Drug Design Based on Principles of Blood‐Brain Barrier Transport (1998) (419)
- Selective expression of the large neutral amino acid transporter at the blood-brain barrier. (1999) (416)
- Strategies to advance translational research into brain barriers (2008) (414)
- Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. (1979) (413)
- Delivery of peptides and proteins through the blood-brain barrier. (1993) (386)
- Drug and Gene Delivery to the Brain The Vascular Route (2002) (382)
- Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. (1997) (377)
- Human Blood—Brain Barrier Insulin Receptor (1985) (373)
- KINETICS OF COMPETITIVE INHIBITION OF NEUTRAL AMINO ACID TRANSPORT ACROSS THE BLOOD‐BRAIN BARRIER (1977) (359)
- Blood-brain barrier transcytosis of insulin in developing rabbits (1987) (344)
- Human blood-brain barrier transferrin receptor. (1987) (334)
- Drug Delivery to the Brain (1997) (330)
- Intravenous RNA Interference Gene Therapy Targeting the Human Epidermal Growth Factor Receptor Prolongs Survival in Intracranial Brain Cancer (2004) (328)
- Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. (1997) (317)
- Kinetic analysis of blood-brain barrier transport of amino acids. (1975) (313)
- Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: an electron microscopic immunogold study. (1991) (308)
- Receptor-mediated peptide transport through the blood-brain barrier. (1986) (302)
- Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. (1991) (301)
- Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. (1987) (296)
- Thyroid function in nonthyroidal illnesses. (1983) (294)
- CSF, blood-brain barrier, and brain drug delivery (2016) (292)
- Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. (1990) (267)
- KINETICS OF BLOOD‐BRAIN BARRIER TRANSPORT OF PYRUVATE, LACTATE AND GLUCOSE IN SUCKLING, WEANLING AND ADULT RATS (1979) (263)
- Bioavailability of albumin-bound testosterone. (1985) (263)
- Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. (2000) (260)
- Brain-specific expression of an exogenous gene after i.v. administration (2001) (260)
- Blood-Brain Barrier Carrier-Mediated Transport and Brain Metabolism of Amino Acids (1998) (256)
- Human Insulin Receptor Monoclonal Antibody Undergoes High Affinity Binding to Human Brain Capillaries in Vitro and Rapid Transcytosis Through the Blood–Brain Barrier in Vivo in the Primate (1995) (241)
- Expression of the neonatal Fc receptor (FcRn) at the blood–brain barrier (2002) (241)
- Transport of small molecules through the blood-brain barrier: biology and methodology. (1995) (230)
- Neuropeptides and the blood-brain barrier. (1983) (228)
- Drug transport in brain via the cerebrospinal fluid (2011) (227)
- Recent advances in blood-brain barrier transport. (1988) (225)
- Kinetics of blood-brain transport of hexoses. (1975) (221)
- Molecular Trojan horses for blood-brain barrier drug delivery. (2006) (214)
- Peptide drug delivery to the brain (1991) (207)
- Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein. (1989) (207)
- Synthesis of Pegylated Immunonanoparticles (2002) (205)
- Mediated efflux of IgG molecules from brain to blood across the blood–brain barrier (2001) (201)
- Molecular biology of the blood-brain barrier (2005) (192)
- Neuroprotection with noninvasive neurotrophin delivery to the brain. (1999) (189)
- Downregulation of Blood-Brain Barrier Glucose Transporter in Experimental Diabetes (1990) (187)
- 4 Serum bioavailability of sex steroid hormones (1986) (186)
- Neutral amino acid transport at the human blood-brain barrier. (1986) (183)
- Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. (2003) (182)
- Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. (1995) (173)
- Biopharmaceutical drug targeting to the brain (2010) (171)
- Brain Drug Targeting: The Future of Brain Drug Development (2001) (171)
- Neuroprotection in Transient Focal Brain Ischemia After Delayed Intravenous Administration of Brain-Derived Neurotrophic Factor Conjugated to a Blood-Brain Barrier Drug Targeting System (2001) (171)
- Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor (2000) (168)
- A Direct In Vitro Demonstration of Insulin Binding to Isolated Brain Microvessels (1981) (168)
- Humanization of anti‐human insulin receptor antibody for drug targeting across the human blood–brain barrier (2007) (167)
- Global non-viral gene transfer to the primate brain following intravenous administration. (2003) (166)
- GLUT1 glucose transporter expression in the diabetic and nondiabetic human eye. (1994) (166)
- Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. (2012) (165)
- Binding and Internalization of Insulin and Insulin-Like Growth Factors by Isolated Brain Microvessels (1986) (163)
- Alzheimer's disease drug development and the problem of the blood-brain barrier (2009) (160)
- shRNA and siRNA delivery to the brain. (2007) (160)
- Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain (2020) (157)
- Noninvasive gene targeting to the brain. (2000) (157)
- Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. (2008) (157)
- Blood-brain barrier: interface between internal medicine and the brain. (1986) (156)
- Brain Microvascular and Astrocyte Localization of P‐Glycoprotein (1997) (156)
- Upregulation of Blood-Brain Barrier GLUT1 Glucose Transporter Protein and mRNA in Experimental Chronic Hypoglycemia (1995) (156)
- Conjugation of brain-derived neurotrophic factor to a blood–brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin (2001) (155)
- Blood–brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion (2006) (153)
- Transport of Human Recombinant Brain-Derived Neurotrophic Factor (BDNF) Through the Rat Blood−Brain Barrier in Vivo Using Vector-Mediated Peptide Drug Delivery (1994) (153)
- Human blood-brain barrier insulin-like growth factor receptor. (1988) (152)
- Receptor-Mediated Gene Targeting to Tissues In Vivo Following Intravenous Administration of Pegylated Immunoliposomes (2001) (150)
- Carrier-mediated transport of thyroid hormones through the rat blood-brain barrier: primary role of albumin-bound hormone. (1979) (148)
- Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. (1993) (146)
- Antisense gene therapy of brain cancer with an artificial virus gene delivery system. (2002) (143)
- Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. (1994) (141)
- Transport of [125I]transferrin through the rat blood-brain barrier (1995) (140)
- Why is the global CNS pharmaceutical market so under-penetrated? (2002) (133)
- Rapid transferrin efflux from brain to blood across the blood–brain barrier (2001) (133)
- Palmitate and Cholesterol Transport Through the Blood‐Brain Barrier (1980) (129)
- Vector-mediated drug delivery to the brain. (1999) (128)
- Receptor‐mediated delivery of an antisense gene to human brain cancer cells (2002) (127)
- Phenylalanine transport at the human blood-brain barrier. Studies with isolated human brain capillaries. (1986) (125)
- Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. (2007) (125)
- Tracer kinetic model of blood-brain barrier transport of plasma protein-bound ligands. Empiric testing of the free hormone hypothesis. (1984) (124)
- PEKMEABILITY CHANGES IN THE BLOOD-BRAIN BARRIER: CAUSES AND CONSEQUENCES* (1975) (124)
- Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. (1997) (124)
- Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood‐brain barrier (2008) (124)
- Blood–brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody (2015) (123)
- Plasma protein-mediated transport of steroid and thyroid hormones. (1987) (122)
- Serum bioavailability of sex steroid hormones. (1986) (122)
- Intravenous siRNA of Brain Cancer with Receptor Targeting and Avidin–Biotin Technology (2007) (121)
- In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats (2003) (120)
- Glucose Deprivation Causes Posttranscriptional Enhancement of Brain Capillary Endothelial Glucose Transporter Gene Expression via GLUT1 mRNA Stabilization (1993) (120)
- Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. (2002) (120)
- Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. (2004) (117)
- Transport of propranolol and lidocaine through the rat blood-brain barrier. Primary role of globulin-bound drug. (1983) (114)
- The brain-type glucose transporter mRNA is specifically expressed at the blood-brain barrier. (1990) (114)
- GLUT-1 glucose transporter is present within apical and basolateral membranes of brain epithelial interfaces and in microvascular endothelia with and without tight junctions. (1992) (114)
- Transport of Albumin‐bound Melatonin Through the Blood‐Brain Barrier (1980) (113)
- Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. (1997) (112)
- Combined Use of Carboxyl-Directed Protein Pegylation and Vector-Mediated Blood-Brain Barrier Drug Delivery System Optimizes Brain Uptake of Brain-Derived Neurotrophic Factor Following Intravenous Administration (1998) (112)
- Rapid Sequestration and Degradation of Somatostatin Analogues by Isolated Brain Microvessels (1985) (112)
- Immunoreactive A4 and gamma-trace peptide colocalization in amyloidotic arteriolar lesions in brains of patients with Alzheimer's disease. (1990) (112)
- Intravenous, non-viral RNAi gene therapy of brain cancer (2004) (111)
- Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood–brain barrier delivery in the mouse (2009) (109)
- Delivery of β-Galactosidase to Mouse Brain via the Blood-Brain Barrier Transferrin Receptor (2005) (108)
- Introduction to the blood-brain barrier : methodology, biology, and pathology (2006) (108)
- Kinetics of Transport and Phosphorylation of 2‐Fluoro‐2‐Deoxy‐d‐Glucose in Rat Brain (1983) (106)
- Enkephalin and blood-brain barrier: studies of binding and degradation in isolated brain microvessels. (1981) (106)
- Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology (2017) (106)
- In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. (1994) (105)
- The Interaction of Transport and Metabolism on Brain Glucose Utilization: A Reevaluation of the Lumped Constant (1981) (105)
- Blood–Brain Barrier Transport of Valproic Acid (1985) (103)
- P-glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries (1999) (102)
- Evaluation of cationized rat albumin as a potential blood-brain barrier drug transport vector. (1990) (101)
- Blood–brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery (2015) (101)
- Kinetic Constants for Blood—Brain Barrier Amino Acid Transport in Conscious Rats (1985) (101)
- The Blood-brain barrier : cellular and molecular biology (1993) (101)
- Restricted Transport of Vitamin D and A Derivatives Through the Rat Blood‐Brain Barrier (1985) (101)
- Kinetics of Regional Blood–Brain Barrier Transport and Brain Phosphorylation of Glucose and 2‐Deoxyglucose in the Barbiturate–Anesthetized Rat (1982) (101)
- Restrictive Transport of a Lipid‐Soluble Peptide (Cyclosporin) Through the Blood–Brain Barrier (1985) (98)
- Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. (2003) (98)
- Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems. (1999) (97)
- hnRNP A2 and hnRNP L bind the 3'UTR of glucose transporter 1 mRNA and exist as a complex in vivo. (1999) (97)
- Targeted delivery of protein and gene medicines through the blood–brain barrier (2015) (94)
- Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. (1997) (94)
- Transferrin-antibody fusion proteins are effective in brain targeting. (1995) (94)
- Up‐Regulation of Blood‐Brain Barrier Short‐Form Leptin Receptor Gene Products in Rats Fed a High Fat Diet (1998) (93)
- Restricted transport of 3'-azido-3'-deoxythymidine and dideoxynucleosides through the blood-brain barrier. (1988) (92)
- Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. (2010) (92)
- Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex. (1995) (91)
- Targeting neurotherapeutic agents through the blood-brain barrier. (2002) (90)
- Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial (2018) (88)
- Blood-Brain Barrier Transport of Reduced Folic Acid (1999) (87)
- Molecular cloning of the bovine blood-brain barrier glucose transporter cDNA and demonstration of phylogenetic conservation of the 5′-untranslated region (1990) (87)
- Enhanced Insulin Binding to Blood-Brain Barrier In Vivo and to Brain Microvessels In Vitro in Newborn Rabbits (1985) (87)
- GDNF fusion protein for targeted‐drug delivery across the human blood–brain barrier (2008) (87)
- Blood-Brain Barrier Genomics (2007) (87)
- Carboxyl-directed Pegylation of Brain-derived Neurotrophic Factor Markedly Reduces Systemic Clearance with Minimal Loss of Biologic Activity (1997) (87)
- Brain Protection from Stroke with Intravenous TNFα Decoy Receptor-Trojan Horse Fusion Protein (2012) (86)
- Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain. (1992) (86)
- Tryptophan transport through the blood-brain barrier: in vivo measurement of free and albumin-bound amino acid. (1979) (86)
- Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues in vivo. (2001) (86)
- Intravenous glial‐derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter (2008) (85)
- An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain. (1999) (84)
- Imaging Brain Amyloid of Alzheimer Disease in Vivo in Transgenic Mice with an Aβ Peptide Radiopharmaceutical (2002) (83)
- Insulin receptor antibody‐iduronate 2‐sulfatase fusion protein: Pharmacokinetics, anti‐drug antibody, and safety pharmacology in Rhesus monkeys (2014) (83)
- The blood-brain barrier and neurotherapeutics (2011) (83)
- Crossing the blood-brain barrier: are we getting it right? (2001) (82)
- Blood-brain barrier transport and brain metabolism of adenosine and adenosine analogs. (1994) (82)
- Immunohistochemical study of cerebral amyloid angiopathy. III. Widespread alzheimer A4 peptide in cerebral microvessel walls colocalizes with gamma trace in patients with leukoencephalopathy (1990) (82)
- Blood—Brain Barrier Transport of Butanol and Water Relative to N-Isopropyl-p-Iodoamphetamine as the Internal Reference (1985) (82)
- Log(BB), PS products and in silico models of drug brain penetration. (2004) (81)
- Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. (1992) (81)
- Transport of protein-bound steroid hormones into liver in vivo. (1979) (80)
- Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family. (1992) (79)
- Transport of Tryptophan into Brain from the Circulating, Albumin‐Bound Pool in Rats and in Rabbits (1990) (79)
- Astrocyte Growth Stimulation by a Soluble Factor Produced by Cerebral Endothelial Cellsin vitro (1990) (78)
- Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood–brain barrier (2007) (77)
- Cloned Blood–Brain Barrier Adenosine Transporter is Identical to the Rat Concentrative Na+ Nucleoside Cotransporter CNT2 (2001) (77)
- Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. (1996) (76)
- Glucose deprivation and hypoxia increase the expression of the GLUT1 glucose transporter via a specific mRNA cis‐acting regulatory element (2002) (76)
- Absence of albumin receptor on brain capillaries in vivo or in vitro. (1985) (75)
- Drug Targeting of Erythropoietin Across the Primate Blood-Brain Barrier with an IgG Molecular Trojan Horse (2010) (75)
- Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses. (2007) (74)
- Blood—Brain Barrier Genomics (2001) (74)
- Gene therapy of the brain (2004) (74)
- Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein. (2011) (74)
- Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. (2010) (74)
- Monoclonal antibody radiopharmaceuticals: cationization, pegylation, radiometal chelation, pharmacokinetics, and tumor imaging. (2003) (73)
- Enhanced cellular uptake of biotinylated antisense oligonucleotide or peptide mediated by avidin, a cationic protein (1991) (73)
- Transport of Insulin‐Related Peptides and Glucose across the Blood‐Brain Barrier a (1993) (73)
- Blood-brain barrier transport of nutrients. (2009) (73)
- Influx of thyroid hormones into rat liver in vivo. Differential availability of thyroxine and triiodothyronine bound by plasma proteins. (1980) (73)
- Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier. (1987) (72)
- The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier (2011) (70)
- Examination of Blood‐Brain Barrier Transferrin Receptor by Confocal Fluorescent Microscopy of Unfixed Isolated Rat Brain Capillaries (1998) (70)
- Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. (1999) (70)
- Carotid Artery Injection Technique: Bounds for Bolus Mixing by Plasma and by Brain (1985) (70)
- Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins. (2002) (70)
- Pathological upregulation of inner blood-retinal barrier Glut1 glucose transporter expression in diabetes mellitus (1996) (69)
- Demonstration and structural comparison of receptors for insulin-like growth factor-I and -II (IGF-I and -II) in brain and blood-brain barrier. (1987) (68)
- Drug and gene targeting to the brain via blood–brain barrier receptor-mediated transport systems (2005) (68)
- Absence of Toxicity of Chronic Weekly Intravenous Gene Therapy with Pegylated Immunoliposomes (2003) (67)
- Neurotrophins, neuroprotection and the blood-brain barrier. (2002) (67)
- Differential expression of α‐actin mRNA and immunoreactive protein in brain microvascular pericytes and smooth muscle cells (1994) (66)
- An Electron Microscopic Immunogold Analysis of Developmental Up-Regulation of the Blood—Brain Barrier GLUT1 Glucose Transporter (1993) (66)
- Effects of human serum on transport of testosterone and estradiol into rat brain. (1980) (66)
- Tyrosine hydroxylase replacement in experimental Parkinson’s disease with transvascular gene therapy (2011) (66)
- Brain Microvascular P-Glycoprotein and a Revised Model of Multidrug Resistance in Brain (2000) (65)
- Kinetics of Neutral Amino Acid Transport Through the Blood‐Brain Barrier of the Newborn Rabbit (1982) (65)
- Transport of histone through the blood-brain barrier. (1989) (65)
- Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. (1998) (64)
- Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology. (2002) (64)
- BBB-Genomics: creating new openings for brain-drug targeting. (2001) (64)
- Blood-Brain Barrier Transport of 125I-Labeled Basic Fibroblast Growth Factor (2004) (64)
- The role of blood-brain barrier transport of tryptophan and other neutral amino acids in the regulation of substrate-limited pathways of brain amino acid metabolism. (1979) (63)
- Advances in cell biology of blood-brain barrier transport. (1991) (63)
- Blood-brain barrier genomics and the use of endogenous transporters to cause drug penetration into the brain. (2003) (63)
- A One‐Step Procedure for Isolation of Poly(A)+ mRNA from Isolated Brain Capillaries and Endothelial Cells in Culture (1991) (63)
- Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease. (2017) (63)
- Beta-endorphin chimeric peptides: transport through the blood-brain barrier in vivo and cleavage of disulfide linkage by brain. (1990) (62)
- Nomogram for 2-Deoxyglucose Lumped Constant for Rat Brain Cortex (1982) (62)
- Blood–Brain Barrier Protein and Phosphorylation and Dephosphorylation (1985) (62)
- Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. (2004) (62)
- Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. (1999) (61)
- Enhanced hepatic extraction of estrogens used for replacement therapy. (1986) (61)
- Influence of blood components on the tissue uptake indices of cyclosporin in rats. (1988) (61)
- Antisense imaging of gene expression in the brain in vivo. (2000) (61)
- Genetically engineered brain drug delivery vectors: cloning, expression and in vivo application of an anti-transferrin receptor single chain antibody-streptavidin fusion gene and protein. (1999) (61)
- Use of neutral avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate. (1994) (61)
- Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. (2009) (60)
- Amyloid Angiopathy of Alzheimer's Disease: Amino Acid Composition and Partial Sequence of a 4,200‐Dalton Peptide Isolated from Cortical Microvessels (1987) (60)
- Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor (2013) (60)
- Brain drug targeting and gene technologies. (2001) (60)
- P-glycoprotein and caveolin-1alpha in endothelium and astrocytes of primate brain. (2003) (59)
- Immunohistochemical study of cerebral amyloid angiopathy. II. Enhancement of immunostaining using formic acid pretreatment of tissue sections. (1988) (58)
- Blood-brain barrier transport of neuropeptides: analysis with a metabolically stable dermorphin analogue. (1994) (58)
- Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. (2013) (57)
- Vascular Genomics of the Human Brain (2002) (57)
- Developmental modulation of blood-brain barrier and choroid plexus GLUT1 glucose transporter messenger ribonucleic acid and immunoreactive protein in rabbits. (1993) (57)
- Potential effects of the dipeptide sweetener aspartame on the brain (1986) (56)
- Subtractive Expression Cloning Reveals High Expression of CD46 at the Blood‐Brain Barrier (2002) (56)
- Molecular biology of the blood-brain barrier. (2005) (56)
- Comparison of Blood-Brain Barrier Transport of Glial-Derived Neurotrophic Factor (GDNF) and an IgG-GDNF Fusion Protein in the Rhesus Monkey (2009) (56)
- Ten nucleotide cis element in the 3'-untranslated region of the GLUT1 glucose transporter mRNA increases gene expression via mRNA stabilization. (1998) (56)
- Determination of in vivo steady-state unbound drug concentration in the brain interstitial fluid by microdialysis (1992) (55)
- Insulin Receptor Antibody–Sulfamidase Fusion Protein Penetrates the Primate Blood–Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type A Cells (2014) (54)
- Near Complete Rescue of Experimental Parkinson’s Disease with Intravenous, Non-viral GDNF Gene Therapy (2009) (54)
- Recent developments in peptide drug delivery to the brain. (1992) (54)
- Differential glycosylation of the GLUT1 glucose transporter in brain capillaries and choroid plexus. (1994) (54)
- Brain Drug Development and Brain Drug Targeting (2007) (54)
- Blood-brain barrier transport and brain sequestration of propranolol and lidocaine. (1984) (54)
- Lysosomal Enzyme Replacement of the Brain with Intravenous Non-Viral Gene Transfer (2008) (53)
- Vector-mediated peptide drug delivery to the brain. (1995) (53)
- Blood-brain barrier glucose transporter mRNA is increased in experimental diabetes mellitus. (1989) (53)
- Brain drug delivery and blood–Brain barrier transport (1993) (53)
- Cationization of immunoglobulin G results in enhanced organ uptake of the protein after intravenous administration in rats and primate. (1991) (52)
- Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. (1996) (52)
- Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization. (1995) (52)
- Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood–brain barrier (2010) (52)
- Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein. (2017) (52)
- Neuroprotection with a Brain-Penetrating Biologic Tumor Necrosis Factor Inhibitor (2011) (52)
- Neutral amino acid transport at the human blood-brain barrier. (1988) (52)
- Antibodies to Blood—Brain Barrier Bind Selectively to Brain Capillary Endothelial Lateral Membranes and to a 46K Protein (1986) (52)
- Influx of testosterone-binding globulin (TeBG) and TeBG-bound sex steroid hormones into rat testis and prostate. (1988) (51)
- Brain amyloid and Alzheimer disease. (1988) (51)
- Pharmacokinetics and Brain Uptake of Biotinylated Basic Fibroblast Growth Factor Conjugated to a Blood-Brain Barrier Drug Delivery System (2002) (50)
- Human brain microvascular DR‐antigen (1989) (49)
- Permeability changes in the blood-brain barrier: causes and consequences. (1975) (49)
- Gene targeting in vivo with pegylated immunoliposomes. (2003) (49)
- Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery (2020) (48)
- Glycemic Control and Chronic Dosing of Rhesus Monkeys with a Fusion Protein of Iduronidase and a Monoclonal Antibody Against the Human Insulin Receptor (2012) (48)
- AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. (2009) (48)
- Blood-brain barrier transport and brain sequestration of steroid hormones. (1980) (48)
- Colocalization of GLUT2 Glucose Transporter, Sodium/glucose Cotransporter, and γ-Glutamyl Transpeptidase in Rat Kidney With Double-Peroxidase Immunocytochemistry (1992) (47)
- Marked enhancement in gene expression by targeting the human insulin receptor (2003) (47)
- Enhanced expression of the blood-brain barrier GLUT1 glucose transporter gene by brain-derived factors. (1994) (47)
- Antisense-mediated down-regulation of the human huntingtin gene. (2000) (46)
- Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide. (2013) (46)
- Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier. (2010) (46)
- Testosterone transport in brain: primary role of plasma protein-bound hormone. (1985) (46)
- Transport of nutrients and hormones through the blood-brain barrier (1981) (46)
- Selective Delivery of Sex Steroid Hormones to Tissues In Vivo by Albumin and by Sex Hormone‐Binding Globulin a (1988) (46)
- Differential permeability of uterine and liver vascular beds to estrogens and estrogen conjugates. (1984) (45)
- Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. (1999) (45)
- In vivo cleavability of a disulfide-based chimeric opioid peptide in rat brain. (1995) (45)
- Abeta(1-40) peptide radiopharmaceuticals for brain amyloid imaging: (111)In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections. (2000) (45)
- Re-engineering therapeutic antibodies for Alzheimer’s disease as blood-brain barrier penetrating bi-specific antibodies (2016) (44)
- Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain. (2011) (44)
- Cis‐Element/Cytoplasmic Protein Interaction Within the 3′‐Untranslated Region of the GLUT1 Glucose Transporter mRNA (1996) (44)
- Liver uptake of amino acids and carbohydrates during a single circulatory passage. (1975) (44)
- Insulin Binding to the Blood‐Brain Barrier in the Streptozotocin Diabetic Rat (1986) (44)
- In vivo quantification of receptor-mediated uptake of asialoglycoproteins by rat liver. (1983) (43)
- Low blood–brain barrier permeability to azidothymidine (AZT), 3TC™, and thymidine in the rat (1998) (43)
- Widespread expression of an exogenous gene in the eye after intravenous administration. (2002) (43)
- Pharmacokinetics and Safety in Rhesus Monkeys of a Monoclonal Antibody-GDNF Fusion Protein for Targeted Blood-Brain Barrier Delivery (2009) (43)
- Kinetics of Regional Blood‐Brain Barrier Glucose Transport and Cerebral Blood Flow Determined with the Carotid Injection Technique in Conscious Rats (1985) (42)
- Enhanced uptake of rsCD4 across the rodent and primate blood-brain barrier after conjugation to anti-transferrin receptor antibodies. (1996) (42)
- Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor. (2018) (41)
- Enhanced endocytosis in cultured human breast carcinoma cells and in vivo biodistribution in rats of a humanized monoclonal antibody after cationization of the protein. (1998) (41)
- Differential expression in glioblastoma multiforme and cerebral hemangioblastoma of cytoplasmic proteins that bind two different domains within the 3'-untranslated region of the human glucose transporter 1 (GLUT1) messenger RNA. (1996) (41)
- Enzymatic barrier protects brain capillaries from leukotriene C4. (1994) (40)
- Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor. (1994) (40)
- Pharmacokinetics of [3H]biotin bound to different avidin analogues. (1995) (40)
- Protein-bound corticosteroid in human serum is selectively transported into rat brain and liver in vivo. (1983) (40)
- Introduction to the Blood–Brain Barrier: Blood–brain barrier methodology and biology (1998) (39)
- Functional and pharmacokinetic properties of antibody-avidin fusion proteins. (1997) (39)
- Hormonal Effects of Danazol and Medical Oophorectomy in Endometriosis (1983) (39)
- Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse (2011) (39)
- Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. (2008) (38)
- Brain-Penetrating IgG-Iduronate 2-Sulfatase Fusion Protein for the Mouse (2012) (38)
- Insulin therapy normalizes GLUT1 glucose transporter mRNA but not immunoreactive transporter protein in streptozocin-diabetic rats. (1993) (38)
- IgG‐single chain Fv fusion protein therapeutic for alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey (2010) (38)
- Differential effect of plasma protein binding of bupivacaine on its in vivo transfer into the brain and salivary gland of rats. (1986) (37)
- Blood-brain barrier and new approaches to brain drug delivery. (1992) (37)
- Blood-brain barrier transport of glucose, free fatty acids, and ketone bodies. (1991) (37)
- New approaches to drug delivery through the blood-brain barrier. (1994) (37)
- Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease. (2018) (37)
- Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse. (2010) (37)
- Chronic Dosing of Mice with a Transferrin Receptor Monoclonal Antibody-Glial-Derived Neurotrophic Factor Fusion Protein (2011) (37)
- Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice. (2013) (37)
- Blood—Brain Barrier Genomics and Cloning of a Novel Organic Anion Transporter (2008) (36)
- Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase. (2010) (36)
- Protamine-mediated transport of albumin into brain and other organs of the rat. Binding and endocytosis of protamine-albumin complex by microvascular endothelium. (1993) (36)
- Monoclonal Antibody-Glial-Derived Neurotrophic Factor Fusion Protein Penetrates the Blood-Brain Barrier in the Mouse (2010) (36)
- Differential kinetics of transport of 2',3'-dideoxyinosine and adenosine via concentrative Na+ nucleoside transporter CNT2 cloned from rat blood-brain barrier. (2001) (36)
- Insulin Receptor Antibody-α-N-Acetylglucosaminidase Fusion Protein Penetrates the Primate Blood-Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type B Fibroblasts. (2016) (36)
- Neuroprotection in stroke in the mouse with intravenous erythropoietin–Trojan horse fusion protein (2011) (35)
- Immunohistochemical study of cerebral amyloid angiopathy: use of an antiserum to a synthetic 28-amino-acid peptide fragment of the Alzheimer's disease amyloid precursor. (1988) (35)
- Molecular Trojan horses for blood-brain barrier drug delivery. (2006) (35)
- Rat Blood–Brain Barrier Genomics. II (2002) (35)
- High Expression of the Gluti Glucose Transporter in Human Brain Hemangioblastoma Endothelium (1995) (34)
- Preferential release of triiodothyronine: an intrathyroidal adaptation to reduced serum thyroxine in aging rats. (1983) (34)
- Complete protection of antisense oligonucleotides against serum nuclease degradation by an avidin-biotin system. (1992) (34)
- Increased Blood—Brain Barrier Transport of Protein-Bound Anticonvulsant Drugs in the Newborn (1983) (34)
- Measurement of Blood‐Brain Barrier GLUT1 Glucose Transporter and Actin mRNA by a Quantitative Polymerase Chain Reaction Assay (1994) (34)
- Brain-Penetrating Tumor Necrosis Factor Decoy Receptor in the Mouse (2011) (34)
- Transport of thyroid and steroid hormones through the blood-brain barrier of the newborn rabbit: primary role of protein-bound hormone. (1980) (34)
- Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG‐iduronate‐2‐sulfatase fusion protein (2011) (34)
- Differential binding of testosterone and estradiol to isoforms of sex hormone-binding globulin: selective alteration of estradiol binding in cirrhosis. (1988) (34)
- Brain Capillary 46,000 Dalton Protein is Cytoplasmic Actin and is Localized to Endothelial Plasma Membrane (1989) (33)
- Insulin binding to brain microvessels. (1983) (33)
- Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody. (1998) (33)
- Pharmacokinetics and organ clearance of a 3'-biotinylated, internally [32P]-labeled phosphodiester oligodeoxynucleotide coupled to a neutral avidin/monoclonal antibody conjugate. (1995) (33)
- Genetic engineering of IgG-glucuronidase fusion proteins (2010) (33)
- Brain Delivery of Biotin Bound to a Conjugate of Neutral Avidin and Cationized Human Albumin (1994) (32)
- Blood-Brain Barrier Disruption Following the Internal Carotid Arterial Perfusion of Alkyl Glycerols (2002) (32)
- The effect of membrane permeability and binding by human serum proteins on sex steroid influx into the uterus. (1983) (32)
- Serum bioavailability and tissue metabolism of testosterone and estradiol in rat salivary gland. (1986) (32)
- Evidence for Translational Control Elements Within the 5′‐Untranslated Region of GLUT1 Glucose Transporter mRNA (1996) (31)
- Blood-brain barrier genomics. (2001) (31)
- Strategies for drug delivery through the blood-brain barrier (1989) (31)
- Differential expression of alpha-actin mRNA and immunoreactive protein in brain microvascular pericytes and smooth muscle cells. (1994) (31)
- IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys. (2013) (31)
- Biologic TNFα-inhibitors that cross the human blood-brain barrier (2010) (30)
- William Pardridge discusses the lack of BBB research (2002) (30)
- Organ‐specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice (2004) (30)
- Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes. (1998) (30)
- Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I (2018) (30)
- Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier. (2009) (29)
- Vascular Proteomics and Subtractive Antibody Expression Cloning* (2002) (29)
- Hypoxia induces de‐stabilization of the LAT1 large neutral amino acid transporter mRNA in brain capillary endothelial cells (2003) (28)
- BLOOD-BRAIN BARRIER TRANSPORT (1988) (28)
- Two-Day Starvation Does Not Alter the Kinetics of Blood-Brain Barrier Transport and Phosphorylation of Glucose in Rat Brain (1985) (28)
- Cationization of a monoclonal antibody to the human immunodeficiency virus REV protein enhances cellular uptake but does not impair antigen binding of the antibody. (1994) (28)
- Transport of thyroxine bound to human prealbumin into rat liver. (1985) (28)
- Development and in vitro characterization of a cationized monoclonal antibody against beta A4 protein: a potential probe for Alzheimer's disease. (1994) (27)
- Inorganic mercury: selective effects on blood‐brain barrier transport systems (1976) (27)
- Mechanisms of Neuropeptide Interaction with the Blood‐Brain Barrier a (1986) (27)
- Complete inactivation of target mRNA by biotinylated antisense oligodeoxynucleotide-avidin conjugates. (1994) (27)
- Androgens and sexual behavior. (1982) (27)
- Combination stroke therapy in the mouse with blood–brain barrier penetrating IgG–GDNF and IgG–TNF decoy receptor fusion proteins (2013) (27)
- Stereospecificity of triiodothyronine transport into brain, liver, and salivary gland: role of carrier- and plasma protein-mediated transport. (1987) (26)
- Critical illness and low testosterone: effects of human serum on testosterone transport into rat brain and liver. (1983) (26)
- The Isolated Brain Microvessel: A Versatile Experimental Model of the Blood-Brain Barrier (2020) (26)
- Site-directed mutagenesis of cysteine residues of large neutral amino acid transporter LAT1. (2005) (26)
- Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse. (2017) (26)
- Brain drug targeting: Drug targeting, drug discovery, and brain drug development (2001) (26)
- The blood-brain barrier: Bottleneck in brain drug development (2005) (25)
- The Ro52/SS-A autoantigen has elevated expression at the brain microvasculature (2003) (25)
- IgG-paraoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier. (2008) (25)
- A Historical Review of Brain Drug Delivery (2022) (25)
- High molecular weight Alzheimer's disease amyloid peptide immunoreactivity in human serum and CSF is an immunoglobulin G. (1987) (25)
- Enhanced endocytosis and anti-human immunodeficiency virus type 1 activity of anti-rev antibodies after cationization. (1994) (25)
- GLUT1 glucose transporter: differential gene transcription and mRNA binding to cytosolic and polysome proteins in brain and peripheral tissues. (1998) (24)
- Regional blood‐brain barrier transport of the steroid hormones (1979) (24)
- Glucose transport and phosphorylation: Which is rate limiting for brain glucose utilization? (1994) (24)
- Glucose and amino acid metabolism in an established line of skeletal muscle cells (1978) (23)
- Drug Targeting to the Brain Using Avidin-Biotin Technology in the Mouse (Blood-Brain Barrier, Monoclonal Antibody, Transferrin Receptor, Alzheimer's Disease) (2000) (23)
- Measurement of Cerebral Glucose Utilization Using Washout After Carotid Injection in the Rat (1982) (23)
- Introduction to the Blood–Brain Barrier: Isolated brain capillaries: an in vitro model of blood–brain barrier research (1998) (23)
- Chapter 31. Strategies for Delivery of Drugs Through the Blood-Brain Barrier (1985) (23)
- Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein. (2011) (22)
- Drug delivery of antisense oligonucleotides or peptides to tissues in vivo using an avidin–biotin system (1993) (22)
- Transport of recombinant CD4 through the rat blood-brain barrier in vivo. (1992) (22)
- Site‐directed mutagenesis of rabbit LAT1 at amino acids 219 and 234 (2003) (22)
- Hepatic bioavailability of serum thyroid hormones in nonthyroidal illness. (1981) (22)
- Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies (2012) (22)
- Neuroprotection in experimental stroke in the rat with an IgG–erythropoietin fusion protein (2010) (22)
- Bioavailable testosterone in salivary glands. (1991) (22)
- Drug transport across the blood–Brain barrier: In Vitro and In Vivo techniques (1998) (22)
- Measurement of Free Intracellular and Transfer RNA Amino Acid Specific Activity and Protein Synthesis in Rat Brain in vivo (1990) (22)
- The safety of aspartame. (1986) (21)
- Transport of nutrients and hormones through the blood-brain barrier. (1981) (21)
- CHO cell expression, long‐term stability, and primate pharmacokinetics and brain uptake of an IgG–paroxonase‐1 fusion protein (2011) (20)
- Decline in Exogenous Gene Expression in Primate Brain Following Intravenous Administration Is Due to Plasmid Degradation (2006) (20)
- Rapid plasma clearance and metabolism in vivo of a phosphorothioate oligodeoxynucleotide with a single, internal phosphodiester bond. (1995) (20)
- Saturable transport of amphetamine across the blood-brain barrier (1973) (19)
- Comparison of cDNA and genomic forms of tyrosine hydroxylase gene therapy of the brain with Trojan horse liposomes (2007) (19)
- Translational science: what is it and why is it so important? (2003) (19)
- Differential expression of 53- and 45-kDa brain capillary-specific proteins by brain capillary endothelium and choroid plexus in vivo and by brain capillary endothelium in tissue culture (1990) (19)
- Unidirectional influx of glutamine and other neutral amino acids into liver of fed and fasted rat in vivo. (1977) (19)
- Plasmid DNA gene therapy of the Niemann-Pick C1 mouse with transferrin receptor-targeted Trojan horse liposomes (2020) (18)
- Plasma pharmacokinetics of high-affinity transferrin receptor antibody-erythropoietin fusion protein is a function of effector attenuation in mice. (2019) (18)
- Preface: Targeted Drug Delivery to the Brain (Blood-Brain Barrier, Efflux, Endothelium, Biological Transport) (2000) (17)
- Very High Plasma Concentrations of a Monoclonal Antibody against the Human Insulin Receptor Are Produced by Subcutaneous Injection in the Rhesus Monkey. (2016) (17)
- Selective delivery of sex steroid hormones to tissues by albumin and by sex hormone-binding globulin. (1988) (17)
- Isolation of intact capillaries and capillary plasma membranes from frozen human brain (1987) (17)
- Does the brain's gatekeeper falter in aging? (1988) (17)
- Human LAT1 single nucleotide polymorphism N230K does not alter phenylalanine transport. (2004) (17)
- Cationized hyperimmune immunoglobulins: pharmacokinetics, toxicity evaluation and treatment of human immunodeficiency virus-infected human-peripheral blood lymphocytes-severe combined immune deficiency mice. (1996) (17)
- Summary: circulating tryptophan, brain tryptophan, and psychiatric disease. (1979) (16)
- Imaging gene expression in regional brain ischemia in vivo with a targeted [111in]-antisense radiopharmaceutical. (2004) (16)
- Mathematical Models of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Transferrin Receptor and the Insulin Receptor (2021) (16)
- Ultrastructural localization of blood-brain barrier-specific antibodies using immunogold-silver enhancement techniques (1991) (16)
- Site‐Directed Deletion of a 10‐Nucleotide Domain of the 3′‐Untranslated Region of the GLUT1 Glucose Transporter mRNA Eliminates Cytosolic Protein Binding in Human Brain Tumors and Induction of Reporter Gene Expression (1997) (16)
- Blood-brain transport of nutrients. Introduction. (1986) (16)
- Holy grails and in vitro blood-brain barrier models. (2004) (16)
- Effects of human cirrhotic serum on estradiol and testosterone transport into rat brain. (1982) (16)
- Enhanced GLUT1 glucose transporter and cytoskeleton gene expression in cultured bovine brain capillary endothelial cells after treatment with phorbol esters and serum. (1992) (16)
- New directions in blood-brain barrier research. Studies with isolated human brain capillaries. (1988) (16)
- Effects of progesterone-binding globulin versus a progesterone antiserum on steroid hormone transport through the blood-brain barrier. (1980) (16)
- Synthesis and bioactivity of monobiotinylated DALDA: a mu-specific opioid peptide designed for targeted brain delivery. (1994) (15)
- Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain (2020) (15)
- Selective Lutheran Glycoprotein Gene Expression at the Blood—Brain Barrier in Normal Brain and in Human Brain Tumors (2000) (15)
- Developmental changes in brain and serum binding of testosterone and in brain capillary uptake of testosterone-binding serum proteins in the rabbit. (1988) (15)
- Non-invasive gene targeting to the fetal brain after intravenous administration and transplacental transfer of plasmid DNA using PEGylated immunoliposomes (2016) (15)
- Bi-functional IgG-lysosomal enzyme fusion proteins for brain drug delivery (2019) (14)
- Branched chain amino acid oxidation in cultured rat skeletal muscle cells. Selective inhibition by clofibric acid. (1980) (14)
- Impermeability of the rat blood-brain barrier to exogenously administered gonadotropin-releasing hormone. (1983) (14)
- Imaging amyloid plaque in Alzheimer's disease brain with a biotinylated Aβ peptide radiopharmaceutical conjugated to an IgG-avidin fusion protein. (2012) (13)
- Pharmacokinetic differences between 111In- and 125I-Labeled cationized monoclonal antibody against β-Amyloid in mouse and dog (1995) (13)
- Alzheimer’s disease: future drug development and the blood-brain barrier (2019) (13)
- CBG does not restrict blood-brain barrier corticosterone transport in rabbits. (1986) (13)
- Kinetics of lactate transport into rat liver in vivo. (1990) (12)
- Hepatic bioavailability of thyroxine and testosterone in familial dysalbuminemic hyperthyroxinemia. (1985) (12)
- Brain drug targeting: Invasive brain drug delivery (2001) (12)
- Developmental Regulation of the Rabbit Blood-Brain Barrier LAT1 Large Neutral Amino Acid Transporter mRNA and Protein (2004) (12)
- Decreases in brain protein synthesis elicited by moderate increases in plasma phenylalanine. (1990) (12)
- Permeability changes in the blood-brain barrier induced by nortriptyline and chlorpromazine. (1973) (12)
- Steady state model of 3,5,3'-triiodothyronine transport in liver predicts high cellular exchangeable hormone concentration relative to in vitro free hormone concentration. (1987) (12)
- An introduction to the blood-brain barrier (1993) (11)
- Alanine metabolism in skeletal muscle in tissue culture. (1979) (11)
- P-glycoprotein and caveolin-1&agr; in endothelium and astrocytes of primate brain (2003) (11)
- Targeting of an anti-CR3 (CD11b/CD18) monoclonal antibody to spleen but not brain, in vivo in mice. (1995) (11)
- Blood flow rate and cellular influx of glucose and arginine in mouse liver in vivo. (1980) (11)
- Lyoprotectant Optimization for the Freeze-Dry of Receptor-Targeted Trojan Horse Liposomes for Plasmid DNA Delivery. (2020) (11)
- Amplification of gene expression using both 5'- and 3'-untranslated regions of GLUT1 glucose transporter mRNA. (1999) (10)
- Hematologic safety of chronic brain-penetrating erythropoietin dosing in APP/PS1 mice (2019) (10)
- Theory and methods for measuring the unidirectional clearance constant for the blood-brain barrier transport of alpha-aminoisobutyric acid. (1983) (10)
- Glucose and amino acid metabolism in neonatal rat skeletal muscle in tissue culture (1980) (9)
- Differential binding of thyroxine and triiodothyronine to acidic isoforms of thyroid hormone binding globulin in human serum. (1988) (9)
- The Blood-Brain Barrier in Alzheimer's Disease (1986) (9)
- In Vivo Availability of Circulating Estradiol in Postmenopausal Women With and Without Endometrial Cancer (1982) (9)
- Differential tissue expression of immunoreactive dehydropeptidase I, a peptidyl leukotriene metabolizing enzyme. (1994) (9)
- Physiologic-based strategies for protein drug delivery to the brain (1996) (9)
- Reduction of testosterone availability to 5α‐reductase by human sex hormone‐binding globulin in the rat ventral prostate gland in vivo (1990) (9)
- Intravenous infusion of iduronidase-IgG and its impact on the central nervous system in children with Hurler syndrome (2017) (8)
- Sir Richard Sykes contemplates the future of the pharma industry. Interview by Rebecca N Lawrence. (2002) (8)
- Kinetics of Blood–Brain Barrier Transport of Monoclonal Antibodies Targeting the Insulin Receptor and the Transferrin Receptor (2021) (8)
- The 5'-untranslated region of GLUT1 glucose transporter mRNA causes differential regulation of the translational rate in plant and animal systems. (1997) (8)
- New opportunities in Asia: a focus on India and China. (2005) (8)
- James Gimzewski discusses the potential of nanobiotechnology (2002) (8)
- Neuropeptides and the blood-brain barrier. (1981) (7)
- Steroid Hormone Transport through Blood–Brain Barrier: Methods and Concepts (1994) (7)
- Preface: Overview of brain drug delivery. (1995) (7)
- William Pardridge discusses the lack of BBB research. Interview by Rebecca N. Lawrence. (2002) (7)
- 6 – Blood-Brain Barrier Transport Mechanisms (1997) (7)
- Effects of dichloroacetate on the lactate/pyruvate ratio and on aspartate and leucine metabolism in cultured rat skeletal muscle cells. (1983) (7)
- Acute and Chronic Dosing of a High-Affinity Rat/Mouse Chimeric Transferrin Receptor Antibody in Mice (2020) (7)
- Measurement of Amyloid Peptide Precursor of Alzheimer Disease in Human Blood by Double Antibody Immunoradiometric Assay (1991) (7)
- Effects of glutamine deprivation on glucose and amino acid metabolism in tissue culture. (1979) (7)
- Blood—brain barrier amino-acid transport: clinical implications (1982) (7)
- Lysine supplementation in hyperargininemia. (1977) (6)
- Treatment of large solid tumors in mice with daunomycin-loaded sterically stabilized liposomes. (1998) (6)
- Low serum thyroxine and high serum triiodothyronine in nephrotic rats: etiology and implications for bioavailability of protein-bound hormone. (1984) (6)
- Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins. (2022) (6)
- Transport of nutrients and hormones through the blood-brain barrier. (1984) (6)
- Molecular Regulation of Blood-Brain Barrier GLUT1 Glucose Transporter (1995) (6)
- Treatment of human immunodeficiency virus-infected lymphocytes with cationized human immunoglobulins. (1994) (6)
- Targeted Delivery of Hormones to Tissues by Plasma Proteins (2011) (6)
- Preclinical studies of a brain penetrating IgG Trojan horse-arylsulfatase fusion protein in the metachromatic leukodystrophy mouse (2019) (5)
- Targets and mechanisms. (2001) (5)
- Brain Capillary Endothelial Transport of Insulin (1992) (5)
- Arginine metabolism and urea synthesis in cultured rat skeletal muscle cells. (1982) (5)
- Red cell phenylalanine is not available for transport through the blood-brain barrier (1990) (5)
- Selective availability of protein bound estrogen and estrogen conjugates to the rat kidney (1987) (5)
- Rapid Publications Colocalization of GLUT2 Glucose Transporter, Sodium/Glucose Cotransporter, and 7-Glutamyl Transpeptidase in Rat Kidney With Double-Peroxidase Immunocytochemistry (1992) (5)
- Antisense radiopharmaceuticals - agents for imaging gene expression. (2001) (5)
- Augmented transport and metabolism of sex steroids in lymphoid neoplasia in the rat. (1987) (5)
- Eliminating Fc N-linked glycosylation and its impact on dosing consideration for a transferrin receptor antibody-erythropoietin fusion protein in mice. (2020) (5)
- Gene targeting technology and gene therapy of the brain. (2001) (4)
- Formulation of therapeutic synthetic polymers for drug and gene delivery. (2002) (4)
- Neuroprotection in stroke: is it time to consider large-molecule drugs? (2001) (4)
- Effects of clofibric acid on amino acid metabolism in cultured rat skeletal muscle. (1981) (4)
- Novel topical and oral treatment for dermatitis and psoriasis. (2001) (4)
- Brain drug targeting: Lipid-mediated transport and carrier-mediated transport of small molecules (2001) (4)
- Safety and clinical efficacy of AGT-181, a brain penetrating human insulin receptor antibody-iduronidase fusion protein, in a 26-week study with pediatric patients with mucopolysaccharidosis type I (2018) (4)
- Brain drug targeting: Vector discovery: genetically engineered Trojan horses for drug targeting (2001) (4)
- The trans-vascular approach (2004) (3)
- Brain drug targeting: Antisense neurotherapeutics and imaging gene expression in vivo (2001) (3)
- Vector-mediated delivery of opioid peptides to the brain. (1995) (3)
- Cellular location of rat muscle ferritins and their preferential loss during cell isolation. (1984) (3)
- Predominant Low‐Molecular‐Weight Proteins in Isolated Brain Capillaries Are Histones (1989) (3)
- 2-07-06 In vivo administration of brain-derived peptides increases the transport of glucose from blood to brain (1997) (3)
- Anti-drug antibody response in mucopolysaccharidosis type I patients treated with AGT-181, a brain penetrating human insulin receptor antibody-iduronidase fusion protein (2018) (3)
- TRYPTOPHAN AND HEPATIC ENCEPHALOPATHY (1975) (3)
- TeBG- and CBG-bound steroid hormones in rabbits are available for influx into uterus in vivo. (1988) (3)
- Re-engineering iduronate 2-sulfatase for penetration of the blood-brain barrier via transport on the insulin receptor (2014) (3)
- Brain drug targeting: Gene therapy of the brain (2001) (3)
- Initial analyses of the human genome: does it reveal anything new? (2001) (3)
- Recursive deconvolution for real-time lead identification (2001) (3)
- Craig Venter discusses life after the Human Genome Project. Interviewed by Rebecca Lawrence. (2001) (3)
- Alastair Devlin discusses the concept of virtual pharma companies. (2001) (2)
- The Safety of Aspartame-Reply (1987) (2)
- Transport of Protein and Antibody Therapeutics Across the Blood–Brain Barrier (2015) (2)
- Localization of Blood-Brain Barrier-Specific Antibodies with Immunogold-Silver Enhancement (1993) (2)
- Short Communication Restrictive Transport of a Lipid-Soluble Peptide (Cyclosporin) Through the Blood- Brain Barrier (1985) (2)
- Blood‐Brain Barrier (2002) (2)
- Blood-Brain Barrier Transport for RNAi (2009) (2)
- Imaging gene expression in the brain with peptide nucleic acid (PNA) antisense radiopharmaceuticals and drug targeting technology (2003) (2)
- Intelligent inhalers for systemic administration? (2001) (2)
- HTS personal perspectives: big pharma. Interview with Manfred Auer (2001) (2)
- HTS personal perspectives: big pharma. Interview with Martin Valler (2001) (1)
- Imaging Gene Expression in Regional Brain Ischemia in Vivo with a Targeted [111In]-Antisense Radiopharmaceutical (2004) (1)
- Delivery and the Brain Barriers (2007) (1)
- Advanced Blood–Brain Barrier Drug Delivery (2022) (1)
- An Interview with a Distinguished Pharmaceutical Scientist: William M. Pardridge, Recipient of the AAPS Meritorious Manuscript Award (1997) (1)
- Predominant Isolated Low-Molecular-Weight Proteins in Brain Capillaries Are Histones (1989) (1)
- New Directions in Blood‐Brain Barrier Research a (1988) (1)
- The effects of membrane permeability and binding by human serum proteins on steroid influx into the rabbit uterus. (1987) (1)
- Brain drug targeting: Receptor-mediated transcytosis of peptides (2001) (1)
- BRAIN BIOPSIES FROM PATIENTS WITH ALZHEIMER DISEASE. IMMUNOHISTOCHEMICAL AND ULTRA-STRUCTURAL STUDY: 76 (1989) (1)
- Platform technology for treatment of the brain in lysosomal disorders: Application to Niemann-Pick disease type A (2019) (1)
- Steven Holtzman discusses partnering. (2001) (1)
- Triiodothyronine bound to red blood cells is not available for transport through the blood-brain barrier (1989) (1)
- A Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease. (2019) (1)
- Short communication Ten nucleotide cis element in the 3 X -untranslated region of the GLUT1 glucose transporter mRNA increases gene expression via mRNA stabilization (1998) (1)
- Administration of anti sensen oligonucleotides and peptides as arzeneimittel to tissues in vivo and to cells by the use of avidin-biotin technology (1992) (1)
- Letter: Water and solute movement through cell membranes. (1974) (1)
- THERAPEUTIC EFFECTS OF A BRAIN PENETRATING BISPECIFIC ERYTHROPOIETIN-TRANSFERRIN RECEPTOR ANTIBODY FUSION PROTEIN IN THE APP/PS1 MOUSE MODEL OF ALZHEIMER’S DISEASE (2018) (1)
- Figure 2, [There are >30 different neurotrophic...]. (2013) (0)
- Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I (2018) (0)
- TracerKinetic ModelofBlood-Brain Barrier Transport ofPlasmaProtein-bound Ligands (1984) (0)
- The Author's Reply (1990) (0)
- PROTECTIVE EFFECTS OF A BRAIN-PENETRATING BIOLOGIC TNF-ALPHA INHIBITOR IN A MOUSE MODEL OF ALZHEIMER’S DISEASE (2017) (0)
- Reply (1994) (0)
- Imaging Brain Amyloid in Alzheimers disease using a Peptide Radiopharmaceutical and a blood-brain barrier drug targeting technology. (2005) (0)
- Platform technology for treatment of the brain in lysosomal disorders: Application to Tay-Sachs disease (2019) (0)
- Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology (2017) (0)
- - 011-0773 TITLE : Non-Invasive Gene Therapy of Experimental Parkinson ' s Disease (0)
- IMMUNOHISTOCHEMICAL STUDY OF CEREBRAL AMYLOID ANGIOPATHY USING AN ANTISERUM TO A SYNTHETIC 28‐AMINO ACID PEPTIDE FRAGMENT OF THE ALZHEIMER'S DISEASE AMYLOID PRECURSOR: 196 (1987) (0)
- The blood-brain barrier and neurotherapeutics (2005) (0)
- Blood–Brain Barrier Targeting of Therapeutic Lysosomal Enzymes (2015) (0)
- Plasma pharmacokinetics of a human insulin receptor antibody-iduronidase fusion protein in patients with mucopolysaccharidosis type I (2018) (0)
- Procede pour stimuler le transport d'anticorps au travers des barrieres capillaires (1991) (0)
- David Bentley discusses life after the Human Genome Project. Interviewed by Rebecca Lawrence. (2001) (0)
- Platform technology for treatment of the brain in lysosomal diseases: Application to NCL1 Batten disease (2019) (0)
- Dendritic vaccine promising for gliomas. (2001) (0)
- Crispin Kirkman discusses the European biotech industry. Interviewed by Ben Ramster and Rebecca N. Lawrence. (2001) (0)
- Biofinance: what does the future hold? (2001) (0)
- New hope for fungal vaccines? (2001) (0)
- HTS personal perspectives: big pharma. Interview with Steve Young (2001) (0)
- What does the human genome sequence mean to you? (2001) (0)
- Letter: Tryptophan and hepatic encephalopathy. (1975) (0)
- Editorial: top-ten start-up companies of 2001 (2002) (0)
- Barrier Drug Targeting System Administration of Brain-Derived Neurotrophic Factor Conjugated to a Blood-Brain Neuroprotection in Transient Focal Brain Ischemia After Delayed Intravenous (2001) (0)
- COMMUNICATION Rapid transferrin efflux from brain to blood across the blood-brain barrier (2001) (0)
- Key industry directors and companies pick up awards. (2001) (0)
- Interleukin proteins provoke antiviral response in asthma (2001) (0)
- Reversing the paradigm for HT protein identification and validation (2001) (0)
- Opioid peptide drug development: transport of opioid chimeric peptides through the blood-brain barrier. (1992) (0)
- Biocomputing: impact of the genomic revolution. (2001) (0)
- Chimeric peptide for the delivery of neuro-peptides through the blood-brain-barrier. (1989) (0)
- Inhibition by indomethacin of increased estradiol extraction by the IUD-containing rat uterine horn. (1985) (0)
- Nutrient Transport through the Blood-Brain Barrier under Normal and Pathological Conditions1 (1983) (0)
- HTS personal perspectives: big pharma. Interview with John Major (2001) (0)
- Tyrosine hydroxylase replacement in experimental Parkinson’s disease with transvascular gene therapy (2005) (0)
- Peptide Transport through the Blood-Brain Barrier (1989) (0)
- Brain drug targeting: Preface (2001) (0)
- Blood-brain barrier from physiology to therapeutics (2015) (0)
- Targeting Protein Therapeutics and Gene Medicines to the Brain (特集・血液脳関門研究の最近の進歩) (2001) (0)
- Treatment of CLN1 disease with a blood-brain barrier penetrating lysosomal enzyme (2022) (0)
- Antisense Drug Delivery to the Brain Targeting : Initial Applications in Anti-HIV Delivery Vehicle for Effective Brain for the Transferrin Receptor Serves as a An Antibody-Avidin Fusion Protein Specific Pardridge (1999) (0)
- Current BER Scientists: Principal Investigators (2001) (0)
- Attempted Rescue of the Phenotype in rpe65–/– Mice by Intravenous Administration of Immunoliposomes Containing an Rpe65 Expression Construct (2004) (0)
- 20 years on: Donald Francis discusses advances in the fight against HIV. (2001) (0)
- Transport of Protein-Bound Radiotracers Into Tissues* (2020) (0)
- HEMATOLOGIC SAFETY OF A BRAIN PENETRATING ERYTHROPOIETIN-TRANSFERRIN RECEPTOR ANTIBODY FUSION PROTEIN IN A MOUSE MODEL OF ALZHEIMER’S DISEASE (2019) (0)
- Brain drug targeting: Protein neurotherapeutics and peptide radiopharmaceuticals (2001) (0)
- O 5 Disulfide-linked chimeric opioid peptides: Bio-activity and in vivo cleavage in rat brain (1996) (0)
- Sarcolemmal protein profiles from cultured myotubes and myoblasts (1981) (0)
- Platform technology for treatment of the brain in lysosomal disorders (2018) (0)
- A brain penetrating biologic TNF-alpha inhibitor for Alzheimer’s disease (2016) (0)
- Differential Kinetics of Transport of 2 (cid:1) ,3 (cid:1) -Dideoxyinosine and Adenosine via Concentrative Na (cid:2) Nucleoside Transporter CNT2 Cloned from Rat Blood-Brain Barrier (2001) (0)
- REVIEW —Current Perspective— Brain Drug Targeting and Gene Technologies (2001) (0)
- Non-Invasive Gene Therapy of Experimental Parkinson's Disease (2006) (0)
- Physiologically Based Pharmacokinetic Model of Brain Delivery of Plasma Protein Bound Drugs (2023) (0)
- Transport de liposomes a travers la barriere hemato-encephalique (1997) (0)
- Matters Arising (1982) (0)
- Anticorps cationises administres a travers la barriere sang-cerveau (1988) (0)
- To the Editor (1983) (0)
- Brain gene therapy with Trojan horse lipid nanoparticles (2023) (0)
- Comprar Brain Drug Targeting | William M. Pardridge | 9780521154468 | Cambridge University Press (2010) (0)
- Brain drug targeting: Linker strategies: the engineering of multifunctional drug formulations (2001) (0)
- Cationized antibody for the unsubscribe through the blood-brain barrier. (1988) (0)
- Non-Viral Gene Transfer to the Retina of Mice and Monkeys Following Intravenous Administration (2003) (0)
- Brain drug targeting: References (2001) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With William M Pardridge?
William M Pardridge is affiliated with the following schools:
